AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9283507 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual drug counseling added to group drug counseling
Number of subjects: 480
Study 9283507 — intervention group
Group type: COMPARATOR
Intervention: Group drug counseling alone
Number of subjects: 480
Study 8393895 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral d-fenfluramine
Number of subjects: 12
Study 8393895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2942295 — intervention group
Group type: EXPERIMENTAL
Intervention: Weichang Fuyuan Decoction
Number of subjects: 406
Study 29018051 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA + LTLD
Number of subjects: 701
Study 29018051 — intervention group
Group type: COMPARATOR
Intervention: RFA
Number of subjects: 701
Study 27044486 — intervention group
Group type: EXPERIMENTAL
Intervention: History model (based on Asthma Control Questionnaire score, current smoking, chronic sinusitis, previous hospital admission for asthma, and ≥1 severe exacerbation in the previous year)
Number of subjects: 611
Study 27044486 — intervention group
Group type: EXPERIMENTAL
Intervention: History + spirometry model
Number of subjects: 611
Study 27044486 — intervention group
Group type: EXPERIMENTAL
Intervention: History + spirometry + FeNO model
Number of subjects: 611
Study 27044486 — intervention group
Group type: COMPARATOR
Intervention: External validation of the three models
Number of subjects: 611
Study 24322805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal MyoRing implantation at 250 μm depth
Number of subjects: 0
Study 24322805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal MyoRing implantation at 300 μm depth
Number of subjects: 0
Study 23946472 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening era (post-PSA screening)
Number of subjects: 1207
Study 23946472 — intervention group
Group type: COMPARATOR
Intervention: Pre-PSA screening era
Number of subjects: 1207
Study 21424149 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical incision (group 1)
Number of subjects: 52
Study 21424149 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel incision (group 2)
Number of subjects: 52
Study 21424149 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 52
Study 18325461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 110
Study 18325461 — intervention group
Group type: COMPARATOR
Intervention: Control (no statins)
Number of subjects: 110
Study 16614008 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (n = 9)
Number of subjects: 20
Study 16614008 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 11)
Number of subjects: 20
Study 14636813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (school-based obesity prevention program)
Number of subjects: 1368
Study 14636813 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1368
Study 14636813 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA (Bioelectric Impedance Analysis)
Number of subjects: 1368
Study 14636813 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfolds and combination of methods
Number of subjects: 1368
Study 11776204 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH‐a (150 micrograms/d, i.m.) plus norethindrone (2.5 mg/d, p.o.)
Number of subjects: 77
Study 11776204 — intervention group
Group type: COMPARATOR
Intervention: LHRH‐a (150 micrograms/d, i.m.)
Number of subjects: 77
Study 8634919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydralazine (75 mg qid)
Number of subjects: 0
Study 8634919 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving hydralazine)
Number of subjects: 0
Study 1631944 — intervention group
Group type: EXPERIMENTAL
Intervention: MALG (20 mg/kg/day)
Number of subjects: 173
Study 1631944 — intervention group
Group type: COMPARATOR
Intervention: OKT3 (5 mg/day)
Number of subjects: 173
Study 1631944 — intervention group
Group type: EXPERIMENTAL
Intervention: MALG and OKT3
Number of subjects: 173
Study 3159468 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-methyldopa
Number of subjects: 20
Study 3159468 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 20
Study 29446654 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt containing Lactobacillus gasseri PA-3
Number of subjects: 25
Study 29446654 — intervention group
Group type: COMPARATOR
Intervention: Yoghurt without Lactobacillus gasseri PA-3 (Control)
Number of subjects: 25
Study 29048942 — intervention group
Group type: EXPERIMENTAL
Intervention: Watson MDI program
Number of subjects: 41
Study 27266196 — intervention group
Group type: EXPERIMENTAL
Intervention: Kou Yan Qing Ke Li
Number of subjects: 60
Study 27266196 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% sodium chloride, lidocaine, dexamethasone, vitamin B2 gargle)
Number of subjects: 60
Study 24849445 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% mannitol (2 ml/kg, infused for over 20 min)
Number of subjects: 33
Study 24849445 — intervention group
Group type: COMPARATOR
Intervention: 15% hypertonic saline (0.42 ml/kg, administered as a bolus via a central venous catheter)
Number of subjects: 33
Study 22794787 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 16
Study 22794787 — intervention group
Group type: COMPARATOR
Intervention: Psycho-education (control group)
Number of subjects: 16
Study 20395226 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + N-acetylcysteine (NAC)
Number of subjects: 130
Study 20395226 — intervention group
Group type: COMPARATOR
Intervention: N-acetylcysteine (NAC) alone
Number of subjects: 130
Study 20395226 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin + NAC
Number of subjects: 130
Study 18628697 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR FF genotype
Number of subjects: 189
Study 18628697 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of myocardial infarction
Number of subjects: 189
Study 18628697 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index at age 40
Number of subjects: 189
Study 18628697 — intervention group
Group type: EXPERIMENTAL
Intervention: Long working hours
Number of subjects: 189
Study 18628697 — intervention group
Group type: EXPERIMENTAL
Intervention: Working with night shift
Number of subjects: 189
Study 16649884 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized feedback intervention mailed to participants
Number of subjects: 177
Study 16649884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 177
Study 12794414 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 1 mg/kg iv (group II, n = 15)
Number of subjects: 28
Study 12794414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group I, n = 13)
Number of subjects: 28
Study 11035613 — intervention group
Group type: EXPERIMENTAL
Intervention: Double therapy
Number of subjects: 0
Study 11035613 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 0
Study 8776911 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed educational intervention focusing on detection of psychological distress
Number of subjects: 0
Study 8776911 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1624000 — intervention group
Group type: EXPERIMENTAL
Intervention: Transuterotubal insemination
Number of subjects: 160
Study 1624000 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 160
Study 1624000 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both methods)
Number of subjects: 160
Study 6482651 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 23
Study 6482651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31680111 — intervention group
Group type: EXPERIMENTAL
Intervention: Text/email appointment reminders and education messages
Number of subjects: 257
Study 31680111 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 257
Study 28605472 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT + primaquine (0.25 mg/kg)
Number of subjects: 274
Study 28605472 — intervention group
Group type: COMPARATOR
Intervention: ACT alone
Number of subjects: 274
Study 26608219 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiGraph
Number of subjects: 42
Study 26608219 — intervention group
Group type: EXPERIMENTAL
Intervention: activPAL
Number of subjects: 42
Study 26608219 — intervention group
Group type: EXPERIMENTAL
Intervention: OSPAQ
Number of subjects: 42
Study 26608219 — intervention group
Group type: EXPERIMENTAL
Intervention: WSQ
Number of subjects: 42
Study 24095885 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/fentanyl
Number of subjects: 80
Study 24095885 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane/fentanyl
Number of subjects: 80
Study 21471799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sennoside A+B calcium
Number of subjects: 0
Study 21471799 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate
Number of subjects: 0
Study 18641191 — intervention group
Group type: COMPARATOR
Intervention: 800 microg/d of folic acid for 3 years
Number of subjects: 294
Study 18641191 — intervention group
Group type: COMPARATOR
Intervention: 0, 50, 100, 200, 400, 600, or 800 microg/d of folic acid for 12 weeks
Number of subjects: 294
Study 17238779 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support reminders and computer generated provider feedback
Number of subjects: 0
Study 12676345 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0
Study 12676345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10912897 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (4 mg)
Number of subjects: 16
Study 8729666 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic asthmatics
Number of subjects: 0
Study 8729666 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 8729666 — intervention group
Group type: COMPARATOR
Intervention: Allergic individuals
Number of subjects: 0
Study 1330880 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1000 mg single dose
Number of subjects: 130
Study 1330880 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for 7 days
Number of subjects: 130
Study 6695766 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin added to propranolol (reduced to 120 mg/day)
Number of subjects: 14
Study 6695766 — intervention group
Group type: COMPARATOR
Intervention: Prazosin added after tapering and discontinuing propranolol
Number of subjects: 14
Study 6695766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 30106494 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 570
Study 30106494 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 570
Study 26851987 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMS caps
Number of subjects: 153
Study 26851987 — intervention group
Group type: COMPARATOR
Intervention: MMAS self-report adherence ratings
Number of subjects: 153
Study 25602629 — intervention group
Group type: EXPERIMENTAL
Intervention: COMBO condition (PBIS + SEL)
Number of subjects: 0
Study 25602629 — intervention group
Group type: EXPERIMENTAL
Intervention: PBIS alone
Number of subjects: 0
Study 25602629 — intervention group
Group type: EXPERIMENTAL
Intervention: SEL alone
Number of subjects: 0
Study 25602629 — intervention group
Group type: COMPARATOR
Intervention: BAU (business-as-usual)
Number of subjects: 0
Study 23090620 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine tablet formulation (500 mg)
Number of subjects: 0
Study 23090620 — intervention group
Group type: COMPARATOR
Intervention: Control formulation of capecitabine (500 mg)
Number of subjects: 0
Study 20602506 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 268
Study 20602506 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 268
Study 19120715 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg/d
Number of subjects: 566
Study 19120715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/d
Number of subjects: 566
Study 19120715 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ 320/25 mg/d
Number of subjects: 566
Study 16357487 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment, n=62
Number of subjects: 88
Study 16357487 — intervention group
Group type: COMPARATOR
Intervention: Baseline food intake before GH treatment
Number of subjects: 88
Study 16357487 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum levels
Number of subjects: 88
Study 12448161 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training intervention group
Number of subjects: 46
Study 12448161 — intervention group
Group type: COMPARATOR
Intervention: Control group (not activated)
Number of subjects: 46
Study 10607968 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 37
Study 10607968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 8745024 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyepatches
Number of subjects: 203
Study 8745024 — intervention group
Group type: COMPARATOR
Intervention: Headbox (control)
Number of subjects: 203
Study 16296712 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg once daily)
Number of subjects: 40
Study 16296712 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (30‐60 mg three times daily)
Number of subjects: 40
Study 7211775 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 3 microgram/kg
Number of subjects: 26
Study 7211775 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 6 microgram/kg
Number of subjects: 26
Study 7211775 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 12 microgram/kg
Number of subjects: 26
Study 7211775 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine 10 microgram/kg
Number of subjects: 26
Study 30503386 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of testosterone cypionate
Number of subjects: 12
Study 27669442 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier-load resistance training (3 sets of 8-12 repetitions; n = 16)
Number of subjects: 32
Study 27669442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter-load resistance training (3 sets of 20-25 repetitions; n = 16)
Number of subjects: 32
Study 27669442 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained regular activity habits; n = 14)
Number of subjects: 32
Study 27374668 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.25 or 0.5 mg just before breakfast and dinner twice daily)
Number of subjects: 78
Study 27374668 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (0.25 or 0.5 mg just before meals thrice daily)
Number of subjects: 78
Study 27374668 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (continuing treatment)
Number of subjects: 78
Study 23483320 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib sodium (40 mg) intravenously (IV) at the completion of surgery and once every 12 h for a total of 6 times postoperatively
Number of subjects: 100
Study 23483320 — intervention group
Group type: COMPARATOR
Intervention: placebo (normal saline 2 mL IV at the same time points)
Number of subjects: 100
Study 21724350 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 42
Study 21724350 — intervention group
Group type: EXPERIMENTAL
Intervention: sunitinib
Number of subjects: 42
Study 21724350 — intervention group
Group type: COMPARATOR
Intervention: sorafenib and sunitinib
Number of subjects: 42
Study 19463203 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS), 110 microg
Number of subjects: 536
Study 19463203 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine, 180 mg
Number of subjects: 536
Study 19463203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 17223551 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in the second tertile (range 5.5‐66.1 ng/ml)
Number of subjects: 568
Study 17223551 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels in the third tertile
Number of subjects: 568
Study 17223551 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels above the median for women
Number of subjects: 568
Study 17223551 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D levels above the median for men
Number of subjects: 568
Study 17223551 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin D intake
Number of subjects: 568
Study 15088221 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support treatments targeting appropriate use of the health care system
Number of subjects: 4310
Study 12195181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises and biofeedback treatment
Number of subjects: 83
Study 10204584 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststorage WBC-reduced platelets
Number of subjects: 30
Study 10204584 — intervention group
Group type: COMPARATOR
Intervention: Plasma-depleted platelets
Number of subjects: 30
Study 10204584 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 levels
Number of subjects: 30
Study 7753975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 48
Study 7753975 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 48
Study 2406169 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-visiting system with one or two weekly visits by domiciliary midwives
Number of subjects: 158
Study 2406169 — intervention group
Group type: COMPARATOR
Intervention: Usual policy of the hospitals (control group)
Number of subjects: 158
Study 396653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 75 mg/day for 1 week followed by 50 mg/day for 3 weeks
Number of subjects: 0
Study 396653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ) 100 mg/day for 4 weeks
Number of subjects: 0
Study 396653 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone (CB) 300 mg/day for 1 week followed by 200 mg/day for 3 weeks
Number of subjects: 0
Study 396653 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone (CB)
Number of subjects: 0
Study 396653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (PRZ)
Number of subjects: 0
Study 31480696 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy snacking frequency
Number of subjects: 73
Study 31480696 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-to-day energy intake variability
Number of subjects: 73
Study 31480696 — intervention group
Group type: COMPARATOR
Intervention: Shift-working nurses
Number of subjects: 73
Study 28104402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic women with polycystic ovarian syndrome
Number of subjects: 702
Study 28104402 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic black women
Number of subjects: 702
Study 28104402 — intervention group
Group type: COMPARATOR
Intervention: Non-Hispanic whites
Number of subjects: 702
Study 29443478 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Unification Program (FUP) with housing case management services
Number of subjects: 150
Study 29443478 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Unification Program (FUP)
Number of subjects: 150
Study 23053618 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate CAMP treatment (n = 15)
Number of subjects: 29
Study 23053618 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (delayed treatment; n = 14)
Number of subjects: 29
Study 20976468 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation for 12 weeks
Number of subjects: 0
Study 20976468 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 0
Study 20976468 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0
Study 20976468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20368858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue glue
Number of subjects: 51
Study 20368858 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suturing
Number of subjects: 51
Study 17264451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 93
Study 17264451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 93
Study 14550682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS at 80% of right-hand muscle twitch threshold
Number of subjects: 10
Study 14550682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS at 90% of right-hand muscle twitch threshold
Number of subjects: 10
Study 14550682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS at 100% of right-hand muscle twitch threshold
Number of subjects: 10
Study 14550682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS at 110% of right-hand muscle twitch threshold
Number of subjects: 10
Study 14550682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS at 120% of right-hand muscle twitch threshold
Number of subjects: 10
Study 14550682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS at various intensities
Number of subjects: 10
Study 10693902 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary monitoring
Number of subjects: 0
Study 10693902 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital monitoring
Number of subjects: 0
Study 10693902 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-subject differences
Number of subjects: 0
Study 8863869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) infusions 1 g kg‐1 (n = 23)
Number of subjects: 43
Study 8863869 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone pulse therapy (MPPT) 30 mg kg‐1 (n = 20)
Number of subjects: 43
Study 8863869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 43
Study 8863869 — intervention group
Group type: COMPARATOR
Intervention: Intravenous methylprednisolone pulse therapy (MPPT)
Number of subjects: 43